Joyce James

1.7k citations

19 papers · 1.1k indexed · 1 hit paper · h-index 9

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in ⓘ

Genetics 12
- Chronic Lymphocytic Leukemia Research 9
- Myeloproliferative Neoplasms: Diagnosis and Treatment 2
Hematology 12
- Acute Myeloid Leukemia Research 11
- Chronic Myeloid Leukemia Treatments 10

Co-authors: Robert C. Armstrong (8 shared papers)Mark J. Levis (4 shared papers)Patrick P. Zarrinkar (7 shared papers)Ruwanthi N. Gunawardane (5 shared papers)Michael F. Gardner (6 shared papers)Shripad S. Bhagwat (6 shared papers)Kelly G. Sprankle (3 shared papers)Qi Chao (3 shared papers)
Journals: Blood (7 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)ACS Medicinal Chemistry Letters (1 paper)
Partner nations: United States Japan New Zealand

In The Last Decade

Joyce James

19 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) 2009 · 474 citations

Peers

Countries citing papers authored by Joyce James

Since Specialization

Citations

This map shows the geographic impact of Joyce James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce James more than expected).

Fields of papers citing papers by Joyce James

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce James. The network helps show where Joyce James may publish in the future.

Co-authors

The 25 scholars most cited alongside Joyce James, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joyce James Line = papers co-authored together Joyce James links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood ·Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh Patel, Mark J. Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat Hit paper breakdown →	2009	474
2	Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status Journal of Clinical Oncology ·Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, Guy Gammon, Denise Trone, Robert C. Armstrong, Joyce James, Mark J. Levis	2013	278
3	Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor Journal of Medicinal Chemistry ·Qi Chao, Kelly G. Sprankle, Robert M. Grotzfeld, Andiliy Lai, Todd A. Carter, Anne Marie Velasco, Ruwanthi N. Gunawardane, Merryl Cramer, Michael F. Gardner, Joyce James, Patrick P. Zarrinkar, Hitesh Patel, Shripad S. Bhagwat	2009	167
4	AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study. Blood ·Jörge E. Cortes, James M. Foran, Darejan Ghirdaladze, Marcel P. Devetten, Mamia Zodelava, Peter Holman, Mark J. Levis, Hagop M. Kantarjian, Gautam Borthakur, Joyce James, Patrick P Zarringkar, Ruwanthi N. Gunawardane, Robert C. Armstrong, Norman M. Padre, Wendell Wierenga, Robert Corringham, Mohit Trikha	2009	54
5	Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors Bioorganic & Medicinal Chemistry Letters ·Hitesh Patel, Robert M. Grotzfeld, Andiliy Lai, Shamal A. Mehta, Zdravko V. Milanov, Qi Chao, Kelly G. Sprankle, Todd A. Carter, Anne Marie Velasco, Miles A. Fabian, Joyce James, Daniel K. Treiber, David J. Lockhart, Patrick P. Zarrinkar, Shripad S. Bhagwat	2009	26
6	An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia Xenobiotica ·Madhu Sanga, Joyce James, Joseph Marini, Guy Gammon, Christine Hale, Jianke Li	2016	23
7	Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Sunny Abraham, Michael J. Hadd, Lan P. Tran, Troy Vickers, Janice A. Sindac, Zdravko V. Milanov, Mark W. Holladay, Shripad S. Bhagwat, Helen Hua, Julia M. Ford Pulido, Merryl Cramer, Dana Gitnick, Joyce James, Alan Dao, Barbara Belli, Robert C. Armstrong, Daniel K. Treiber, Gang Liu	2011	13
8	Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3 Blood ·Joyce James, Keith W. Pratz, Adam Stine, Julius Apuy, Darren E. Insko, Robert C. Armstrong, Patrick P. Zarrinkar, Donald Small, Wendell Wierenga, Mark J. Levis	2008	13
9	Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases ACS Medicinal Chemistry Letters ·Gang Liu, Brian T. Campbell, Mark W. Holladay, Julia M. Ford Pulido, Helen Hua, Dana Gitnick, Michael F. Gardner, Joyce James, Mike A. Breider, Daniel Brigham, Barbara Belli, Robert C. Armstrong, Daniel K. Treiber	2012	10
10	Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists Bioorganic & Medicinal Chemistry Letters ·Thomas S. Reger, Jasmine Zunic, Nicholas Stock, Bowei Wang, Nicholas D. Smith, Benito Muñoz, Mitchell D. Green, Michael F. Gardner, Joyce James, Weichao Chen, Kenneth Alves, Qian Si, Kelly Treonze, Russell B. Lingham, Richard A. Mumford	2009	7
11	Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor. Blood ·Jörge E. Cortes, James M. Foran, Marcel P. Devetten, Francis J. Giles, Joyce James, Patrick P. Zarrinkar, Michael H. Silverman, Kerry A. Kelly, Norman M. Padre, Shripad V. Bhagwat, Wendell Wierenga	2007	7
12	Influence of acid surrogates toward potency of VLA-4 antagonist Bioorganic & Medicinal Chemistry Letters ·Shankar Venkatraman, Jongwon Lim, Merryl Cramer, Michael F. Gardner, Joyce James, Kenneth Alves, Russell B. Lingham, Richard A. Mumford, Benito Muñoz	2005	6
13	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3′,5′-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist Bioorganic & Medicinal Chemistry Letters ·Shankar Venkatraman, Alec D. Lebsack, Kenneth Alves, Michael F. Gardner, Joyce James, Russell B. Lingham, Salony Maniar, Richard A. Mumford, Qian Si, Nicholas Stock, Kelly Treonze, Bowei Wang, Jasmine Zunic, Benito Muñoz	2009	6
14	Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers Blood ·Jianke Li, Gayle Bresnahan, Guy Gammon, Madhu Sanga, Christine Hale, Tadashi Hashimoto, Stanley C. Gill, Joyce James	2012	5
15	Abstract 4485: Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR Cancer Research ·David J. Matthews, Marie O’Farrell, Joyce James, Anna C. Giddens, Gordon W. Rewcastle, William A. Denny	2011	4
16	Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status Blood ·Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, Guy Gammon, Denise Trone, Robert C. Armstrong, Joyce James, Mark J. Levis	2012	4
17	Abstract 3078: Tesetaxel, a novel, oral taxane, crosses intact blood-brain barrier (BBB) at therapeutically relevant concentrations Joyce James, Kevin Tang, Thomas Wei	2019	2
18	Abstract #1787: Characterization of the biochemical and cellular activity of the second-generation FLT3 inhibitor AC220 Cancer Research ·Patrick P. Zarrinkar, Robert Armstrong, Ruwanthi N. Gunawardane, Joyce James, Mazen W. Karaman, Shripad S. Bhagwat	2009	1
19	AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor Blood ·Patrick P. Zarrinkar, Robert C. Armstrong, Ruwanthi N. Gunawardane, Joyce James, Mazen W. Karaman, Shripad S. Bhagwat	2008	1

About Joyce James

Joyce James is a scholar working on Genetics, Hematology, Molecular Biology, Oncology and Cellular and Molecular Neuroscience, having authored 19 papers that have together received 1.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (9 papers), Protein Degradation and Inhibitors (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Neuropeptides and Animal Physiology (2 papers), Cell Adhesion Molecules Research (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Hematology (821 citations), Genetics (378 citations), Molecular Biology (490 citations), Oncology (123 citations) and Organic Chemistry (127 citations). Joyce James has collaborated with scholars based in United States, Japan and New Zealand. Frequent co-authors include Robert C. Armstrong, Mark J. Levis, Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Michael F. Gardner, Shripad S. Bhagwat, Kelly G. Sprankle, Qi Chao, Hitesh Patel and Merryl Cramer. Their work appears in journals such as Blood, Bioorganic & Medicinal Chemistry Letters, Cancer Research, Journal of Clinical Oncology and ACS Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact